RWD18 Characterization of Time-to-Treatment-Discontinuation (TTTD) as a Proxy for Progression-Free Survival (PFS) in Real-World Evidence (RWE) Based Analyses of Relapsed-Refractory Multiple Myeloma (RRMM)
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.2736
https://www.valueinhealthjournal.com/article/S1098-3015(23)05866-7/fulltext
Section Title :
Section Order :
12069
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)05866-7&doi=10.1016/j.jval.2023.09.2736